Functional complement assays are essential for diagnosing component deficiencies in inborn errors of immunity 1 and for management of patients receiving complement-inhibiting therapeutics. 2 But as gold standard haemolytic assays are labour-intensive, technically challenging, and difficult to automate, 2 increasing complement inhibitor therapeutic use 3 demands scalable alternatives. Commercially available enzyme-linked immunosorbent assays (ELISAs) and liposome-based assays offer simpler, standardised options and we compared their performance with our in-house haemolytic methods.
Hulme-Jones et al. (Sun,) studied this question.